Document is current
Any future updates will be listed below
-
Authors
Djerroudi, Lounes https://orcid.org/0000-0002-5007-2964
Mhaidly, Rana
Kieffer, Yann https://orcid.org/0000-0003-2722-3071
Damei, Isabelle
Croizer, Hugo
Selvarasa, Vithuzane
Gentric, Geraldine https://orcid.org/0000-0002-7558-8705
Fuhrmann, Laetitia https://orcid.org/0000-0003-1755-6307
Goncalves, Andreia
Caly, Martial
Richardot, Camille
Leclere, Renaud https://orcid.org/0000-0001-8737-6817
Laas, Enora
Malhaire, Caroline https://orcid.org/0000-0002-9235-9816
Cao, Kim
Houthuijzen, Julia M. https://orcid.org/0000-0003-0404-1961
Kloosterman, Pim
Jonkers, Jos https://orcid.org/0000-0002-9264-9792
Benoist, Camille
Renault, Victor
Bidard, François-Clément https://orcid.org/0000-0001-5932-8949
Vincent-Salomon, Anne https://orcid.org/0000-0001-5754-5771
Mechta-Grigoriou, Fatima https://orcid.org/0000-0002-3751-6989
-
Funding
Funding for this research was provided by:
Institut National de la Santé et de la Recherche Médicale (PC201317)
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 27 April 2026
First Online: 12 May 2026
Competing interests
: F.M.-G. and A.V.-S received research support from Roche, Institut Roche and the MSD Foundation. L.D. received research mobility support from Institut Servier. F.-C.B. reports research funding from GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, MSD, Natera, Novartis, Personalis, Pfizer, Prolynx, Roche, SAGADx and Tempus; has served on advisory boards for AstraZeneca, Carrick Therapeutics, Daiichi Sankyo, Hengrui, Inatherys, Lilly, Menarini Silicon Biosystems, Novartis, Pfizer, Relay Therapeutics, Roche and Tempus; and has received speaker honoraria and travel support from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer and Roche. Other authors declare no potential competing interests.
